Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Expert Rev Gastroenterol Hepatol ; 10(1): 93-112, 2016.
Article in English | MEDLINE | ID: mdl-26560258

ABSTRACT

The majority of gallstone patients remain asymptomatic; however, interest toward the gallstone disease is continuing because of the high worldwide prevalence and management costs and the development of gallstone symptoms and complications. For cholesterol gallstone disease, moreover, a strong link exists between this disease and highly prevalent metabolic disorders such as obesity, dyslipidemia, type 2 diabetes, hyperinsulinemia, hypertriglyceridemia and the metabolic syndrome. Information on the natural history as well as the diagnostic, surgical (mainly laparoscopic cholecystectomy) and medical tools available to facilitate adequate management of cholelithiasis and its complications are, therefore, crucial to prevent the negative outcomes of gallstone disease. Moreover, some risk factors for gallstone disease are modifiable and some preventive strategies have become necessary to reduce the onset and the severity of complications.


Subject(s)
Biliary Fistula/etiology , Gallbladder Neoplasms/therapy , Gallstones/complications , Gallstones/therapy , Intestinal Fistula/etiology , Biliary Fistula/complications , Biliary Fistula/surgery , Cholecystectomy , Cholecystitis, Acute/etiology , Cholecystitis, Acute/therapy , Choledocholithiasis/diagnosis , Choledocholithiasis/etiology , Choledocholithiasis/surgery , Gallbladder Neoplasms/diagnosis , Gallstones/classification , Gallstones/diagnosis , Humans , Ileus/etiology , Intestinal Fistula/complications , Intestinal Fistula/surgery , Jaundice, Obstructive/etiology , Pancreatitis/diagnosis , Pancreatitis/surgery , Primary Prevention , Recurrence , Risk Factors , Secondary Prevention
2.
Neurogastroenterol Motil ; 28(3): 364-75, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26604077

ABSTRACT

BACKGROUND: Celiac disease is an autoimmune enteropathy caused by a permanent intolerance to dietary gluten in genetically predisposed individuals. Cholecystokinin (CCK) release from the proximal small intestine and gallbladder emptying in response to a fatty meal are greatly reduced in celiac patients before they start the gluten-free diet, showing a genetic predisposition to gallstones. METHODS: To elucidate the complex pathophysiological mechanisms determining the biliary characteristic of celiac disease, we investigated the effect of the absence of endogenous CCK on cholesterol crystallization and gallstone formation in mice fed a lithogenic diet for 28 days. KEY RESULTS: Fasting gallbladder volumes were increased and the response of gallbladder emptying to the high-fat diet was impaired in CCK knockout (KO) mice compared to wild-type mice. Because of the absence of CCK, small intestinal transit time was prolonged and intestinal cholesterol absorption was increased. During 28 days of feeding, elevated biliary cholesterol concentrations and gallbladder stasis promoted the growth and agglomeration of solid cholesterol crystals into microlithiasis and stones. Thus, cholesterol crystallization and gallstone formation were accelerated in CCK KO mice. In contrast, daily intraperitoneal administration of CCK-8 reduced gallstone formation in CCK KO mice even on the lithogenic diet. CONCLUSIONS & INFERENCES: The lack of endogenous CCK enhances susceptibility to gallstones by impairing gallbladder contractile function and small intestinal motility function. These findings show that celiac disease is an important risk factor for gallstone formation and the gallbladder motility function should be routinely examined by ultrasonography and gallbladder stasis should be prevented in celiac patients.


Subject(s)
Cholecystokinin/deficiency , Gallbladder Emptying/physiology , Gallstones/etiology , Animals , Bile/chemistry , Bile/metabolism , Celiac Disease/complications , Gallstones/metabolism , Gastrointestinal Transit/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Real-Time Polymerase Chain Reaction
3.
Eur J Clin Invest ; 39(11): 986-92, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19656169

ABSTRACT

BACKGROUND: Proteins might act as pronucleating agents of cholesterol crystallization in bile. However, little is known about the redox status of biliary proteins in humans and their interaction with crystallization of biliary cholesterol. MATERIALS AND METHODS: Gallbladder biles were obtained at cholecystectomy from 86 symptomatic patients with either cholesterol gallstones (32 multiple and 32 solitary stones) or pigment stones (n = 22), and studied for protein redox status [carbonyl and sulfhydryl (PSH) concentrations], total lipid and protein levels and cholesterol saturation index (CSI). First appearance of cholesterol crystals in ultrafiltered bile (crystal observation time, COT) was studied with polarizing light microscopy during 21 days. RESULTS: Patients with cholesterol stones had significantly shorter COT (3 days vs. >21 days, P < 0.05), higher CSI (149 +/- 10% vs. 97 +/- 7%, P < 0.05) and higher total biliary proteins (1.96 +/- 0.1 mg mL(-1) vs. 0.55 +/- 0.1 mg mL(-1), P < 0.05) than patients with pigment stones. Patients with cholesterol stones had significantly lower (P < 0.05) level of protein sulfhydryl concentrations (18 +/- 4 nmol mg(-1) protein vs. 49 +/- 16 nmol mg(-1) protein), while total lipid and carbonyl proteins concentrations were similar between cholesterol and pigment stone patients. Crystallization probability was influenced by the number/type of gallstones (multiple > solitary > pigment stones, P = 0.009) and total protein concentration (high > low levels, P = 0.004). COT was negatively correlated with total protein content (r = -0.45, P = 0.03). CONCLUSIONS: Biles with cholesterol stones show high CSI and total protein concentration, and rapid COT, which is even faster in patients with multiple stones and high protein concentration. Low PSH levels in cholesterol stone patients point to a biochemical shift, potentially able to affect cholesterol crystallization.


Subject(s)
Bile/metabolism , Cholelithiasis/metabolism , Cholesterol/metabolism , Proteins/metabolism , Adult , Cholelithiasis/surgery , Female , Humans , Male , Microscopy, Polarization , Middle Aged , Oxidation-Reduction
4.
Eur J Clin Invest ; 38(11): 835-44, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19021701

ABSTRACT

BACKGROUND: A lactose-free diet is commonly prescribed to subjects with hypolactasia. We tested the effectiveness of a single ingestion of tilactase (a beta-D-galactosidase from Aspergillus oryzae) in adults with hypolactasia, previously assessed by lactose H(2)-breath test. MATERIALS AND METHODS: After measurement of orocecal transit time (OCTT, by lactulose H(2)-breath test) and lactose H(2)-breath testing plus placebo, a total of 134 subjects were positive to hypolactasia and underwent lactose H(2)-breath testing plus either low (6750 U) or standard (11,250 U) doses of tilactase. The appearance of gastrointestinal symptoms during the tests was monitored. RESULTS: OCTT was longer in malabsorbers (subjects without bloating, abdominal pain and/or diarrhoea, n = 25) than in intolerants (bloating, abdominal pain and/or diarrhoea, n = 109, P < 0.02). Malabsorbers had longer time to H(2) peak (P < 0.03), lower H(2) peak levels (P < 0.002) and smaller integrated H(2) excretion levels (P < 0.005) than intolerants. After tilactase ingestion, integrated H(2) levels were decreased by 75% (low dose) and 87% (standard dose) in malabsorbers, and by 74% (low dose) and 88% (standard dose) in intolerants. In the latter group, total symptom score were decreased by 76% (low dose) and by 88% (standard dose) (P < 0.0001). CONCLUSION: A single oral administration of tilactase is highly effective in decreasing symptoms and hydrogen excretion of hypolactasia assessed by lactose H(2)-breath test. If confirmed by long-term observations, ingestion of tilactase might be a better option than exclusion diets in intolerant subjects with hypolactasia.


Subject(s)
Lactose Intolerance/drug therapy , beta-Galactosidase/therapeutic use , Abdominal Pain/drug therapy , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Breath Tests , Female , Gastrointestinal Transit/physiology , Humans , Hydrogen/analysis , Lactose Intolerance/diagnosis , Lactose Intolerance/physiopathology , Male , Middle Aged , Young Adult , beta-Galactosidase/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...